Measuring Epstein-Barr virus (EBV) load: the significance and application for each EBV-associated disease

被引：116

作者：

Kimura, Hiroshi ^{[1
]}

Ito, Yoshinori ^{[2
]}

Suzuki, Ritsuro ^{[3
]}

Nishiyama, Yukihiro ^{[1
]}

机构：

[1] Nagoya Univ, Grad Sch Med, Dept Virol, Showa Ku, Nagoya, Aichi 4668550, Japan

[2] Nagoya Univ, Grad Sch Med, Dept Pediat, Nagoya, Aichi 4668550, Japan

[3] Nagoya Univ, Sch Med, Dept HSCT Data Management, Nagoya, Aichi 4668550, Japan

来源：

REVIEWS IN MEDICAL VIROLOGY | 2008年 / 18卷 / 05期

关键词：

D O I：

10.1002/rmv.582

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Because Epstein-Barr virus (EBV) is ubiquitous and persists latently in lymphocytes, simply detecting EBV is insufficient to diagnose EBV-associated diseases. Therefore, measuring the EBV load is necessary to diagnose EBV-associated diseases and to explore EBV pathogenesis. Due to the diverse biology of EBV, the significance of measuring EBV DNA and the optimal type of specimen differ among EBV-associated diseases. Recent advances in molecular technology have enabled the EBV genome to be quantitated rapidly and accurately. Real-time polymerase chain reaction (PCR) is a rapid and reliable method to quantify DNA and is widely used not only as a diagnostic tool, but also as a management tool for EBV-associated diseases. However, each laboratory currently measures EBV load with its own "homebrew" system, and there is no consensus on sample type, sample preparation protocol, or assay units. The EBV real-time PCR assay system must be standardised for large-scale studies and international comparisons. Copyright (C) 2008 John Wiley & Sons, Ltd.

引用

页码：305 / 319

页数：15

共 115 条

[61]

Lei KIK, 2002, CLIN CANCER RES, V8, P29

[62] Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma [J].

Lin, JC ;

Wang, WY ;

Chen, KY ;

Wei, YH ;

Liang, WM ;

Jan, JS ;

Jiang, RS .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (24) :2461-2470

[63] Epstein-Barr virus DNA loads in adult human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy [J].

Ling, PD ;

Vilchez, RA ;

Keitel, WA ;

Poston, DG ;

Peng, RS ;

White, ZS ;

Visnegarwala, F ;

Lewis, DE ;

Butel, JS .

CLINICAL INFECTIOUS DISEASES, 2003, 37 (09) :1244-1249

[64]

Lo YMD, 1999, CANCER RES, V59, P1188

[65]

Lo YMD, 1999, CANCER RES, V59, P5452

[66]

Lo YMD, 2000, CANCER RES, V60, P6878

[67]

Lucas KG, 1998, BLOOD, V91, P3654

[68] Epstein-Barr virus - recent advances [J].

Macsween, KF ;

Crawford, DH .

LANCET INFECTIOUS DISEASES, 2003, 3 (03) :131-140

[69] Persistently high Epstein-Barr virus (EBV) loads in peripheral blood lymphocytes from patients with chronic active EBV infection [J].

Maeda, A ;

Wakiguchi, H ;

Yokoyama, W ;

Hisakawa, H ;

Tomoda, T ;

Kurashige, T .

JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (04) :1012-1015

[70] Impaired recovery of Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease [J].

Meij, P ;

van Esser, JWJ ;

Niesters, HGM ;

van Baarle, D ;

Miedema, F ;

Blake, N ;

Rickinson, AB ;

Leiner, I ;

Pamer, E ;

Löwenberg, B ;

Cornelissen, JJ ;

Gratama, JW .

BLOOD, 2003, 101 (11) :4290-4297

← 2 3 4 5 6 7 8 9 10 11 →